INNOVEX THERAPEUTICS S.L. is the first Spanish company devoted to the valorization of Exosomes and Extracellular Vesicles as new platforms for vaccines and/or diagnostic tools. Cornerstone of the Spin-off is the discovery that reticulocyte-derived exosomes (rex) from malaria infections could be used as a new platform and vaccine against this disease. This approach is internationally protected (PCT/EP2010/070800).
INNOVEX THERAPEUTICS S.L. is a brand new Spin-off co-founded by Hernando A del Portillo and Francesc E. Borrás, with 10% accionary participation of three Research Institutions: